Competing Endogenous RNAs (ceRNAs) and Drug Resistance to Cancer Therapy

Overview

Journal Cancer Drug Resist

Date 2024 Oct 15

PMID 39403602

Authors

Kenneth K W To

Hang Zhang

William C Cho

Affiliations

Soon will be listed here.

Abstract

Competing endogenous RNAs (ceRNAs) are transcripts that possess highly similar microRNA response elements (MREs). microRNAs (miRNAs) are short, endogenous, single-stranded non-coding RNAs (ncRNAs) that can repress gene expression by binding to MREs on the 3' untranslated regions (UTRs) of the target mRNA transcripts to suppress gene expression by promoting mRNA degradation and/or inhibiting protein translation. mRNA transcripts, circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and transcribed pseudogenes could share similar MREs, and they can compete for the same pool of miRNAs. These ceRNAs may affect the level of one another by competing for their shared miRNAs. This interplay between different RNAs constitutes a ceRNA network, which regulates many important biological processes. Cancer drug resistance is a major factor leading to treatment failure in patients receiving chemotherapy. It can be acquired through genetic, epigenetic, and various tumor microenvironment mechanisms. The involvement of ceRNA crosstalk and its disruption in chemotherapy resistance is attracting attention in the cancer research community. This review presents an updated summary of the latest research on ceRNA dysregulation causing drug resistance across different cancer types and chemotherapeutic drug classes. Interestingly, accumulating evidence suggests that ceRNAs may be used as prognostic biomarkers to predict clinical response to cancer chemotherapy. Nevertheless, detailed experimental investigations of the putative ceRNA networks generated by computational algorithms are needed to support their translation for therapeutic and prognostic applications.

Citing Articles

Prognostic and diagnostic value of circRNA expression in cervical cancer: a meta analysis.

Xu Y, Li C, Cheng L, Wang S, Wu Y, Li S Front Oncol. 2025; 14:1488040.

PMID: 39871946 PMC: 11769824. DOI: 10.3389/fonc.2024.1488040.

Dysregulation of transposable elements and PIWI-interacting RNAs in myelodysplastic neoplasms.

Krejcik Z, Kundrat D, Klema J, Hrustincova A, Trsova I, Belickova M Biomark Res. 2025; 13(1):13.

PMID: 39849644 PMC: 11755807. DOI: 10.1186/s40364-025-00725-x.

LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer.

Verma D, Siddharth S, Yende A, Wu Q, Sharma D Cells. 2024; 13(22).

PMID: 39594666 PMC: 11593075. DOI: 10.3390/cells13221918.

References

Zhang D, Lu W, Zhuo Z, Wang Y, Zhang W, Zhang M . Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer. BMC Med Genomics. 2023; 16(1):96. PMC: 10161630. DOI: 10.1186/s12920-023-01511-0. View

Zhang Y, Zhang Y, Tao H, Zhu J, Lu Y, Cheng F . Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy. Cancer Lett. 2023; 576:216405. DOI: 10.1016/j.canlet.2023.216405. View

Zhao L, Liu Y, Zhang J, Liu Y, Qi Q . LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint. Cell Death Dis. 2019; 10(10):731. PMC: 6769008. DOI: 10.1038/s41419-019-1886-5. View

Wei S, Wang K, Huang X, Zhao Z, Zhao Z . LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019; 33:2058738419859699. PMC: 6595645. DOI: 10.1177/2058738419859699. View

Zhang M, Wang N, Song P, Fu Y, Ren Y, Li Z . LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1. Cell Prolif. 2020; 53(9):e12855. PMC: 7507373. DOI: 10.1111/cpr.12855. View

Tay Y, Kats L, Salmena L, Weiss D, Tan S, Ala U . Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011; 147(2):344-57. PMC: 3235920. DOI: 10.1016/j.cell.2011.09.029. View

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

Sabnis A, Bivona T . Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019; 25(3):185-197. PMC: 6401263. DOI: 10.1016/j.molmed.2018.12.009. View

Park H, Ji P, Kim S, Xia Z, Rodriguez B, Li L . 3' UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk. Nat Genet. 2018; 50(6):783-789. PMC: 6689271. DOI: 10.1038/s41588-018-0118-8. View

10.

Cui L, Gouw A, LaGory E, Guo S, Attarwala N, Tang Y . Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nat Biotechnol. 2020; 39(3):357-367. PMC: 7956242. DOI: 10.1038/s41587-020-0707-9. View

11.

Wang P, Guo Q, Qi Y, Hao Y, Gao Y, Zhi H . LncACTdb 3.0: an updated database of experimentally supported ceRNA interactions and personalized networks contributing to precision medicine. Nucleic Acids Res. 2021; 50(D1):D183-D189. PMC: 8728196. DOI: 10.1093/nar/gkab1092. View

12.

Zhang P, Pei X, Li K, Jin L, Wang F, Wu J . Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 2019; 18(1):179. PMC: 6900862. DOI: 10.1186/s12943-019-1111-2. View

13.

Bai W, Peng H, Zhang J, Zhao Y, Li Z, Feng X . LINC00589-dominated ceRNA networks regulate multiple chemoresistance and cancer stem cell-like properties in HER2 breast cancer. NPJ Breast Cancer. 2022; 8(1):115. PMC: 9617889. DOI: 10.1038/s41523-022-00484-0. View

14.

Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T . Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020; 14(3):539-555. PMC: 7053238. DOI: 10.1002/1878-0261.12629. View

15.

Chen C, Shyu A . Emerging Themes in Regulation of Global mRNA Turnover in cis. Trends Biochem Sci. 2016; 42(1):16-27. PMC: 5182187. DOI: 10.1016/j.tibs.2016.08.014. View

16.

Tang C, Deng Y, Shao S, Guo Y, Yang L, Yan Y . Long noncoding RNA UCA1 promotes the expression and function of P-glycoprotein by sponging miR-16-5p in human placental BeWo cells. FASEB J. 2022; 37(1):e22657. DOI: 10.1096/fj.202201051R. View

17.

Gao L, Wu Z, Assaraf Y, Chen Z, Wang L . Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021; 57:100770. DOI: 10.1016/j.drup.2021.100770. View

18.

Xu J, Meng Q, Li X, Yang H, Xu J, Gao N . Long Noncoding RNA MIR17HG Promotes Colorectal Cancer Progression via miR-17-5p. Cancer Res. 2019; 79(19):4882-4895. DOI: 10.1158/0008-5472.CAN-18-3880. View

19.

An Q, Zhou L, Xu N . Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143. Biomed Pharmacother. 2018; 103:415-420. DOI: 10.1016/j.biopha.2018.03.138. View

20.

Wu C, Su J, Long W, Qin C, Wang X, Xiao K . LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR-134/Myc/ABCC1 axis in glioma. J Cell Mol Med. 2020; 24(20):12094-12106. PMC: 7579701. DOI: 10.1111/jcmm.15846. View